Skip to main content
Erschienen in: InFo Hämatologie + Onkologie 4/2022

12.04.2022 | Neuroendokrine Tumoren | Schwerpunkt

Schwerpunkt "Theranostik"

Nicht nur bei NET: Somatostatinrezeptor-gerichtete Theranostik

verfasst von: PD. Dr. med. Manuel Weber

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Auszug

Bei einigen Tumorentitäten werden Rezeptoren für das Peptidhormon Somatostatin überexprimiert. Die gesteigerte Expression dieser Somatostatinrezeptoren (SSTR) lässt sich sowohl für die Bildgebung als auch für therapeutische Ansätze ausnutzen. Eine Übersicht.
Literatur
1.
Zurück zum Zitat Krenning EP et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1(8632):242-4 Krenning EP et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1(8632):242-4
2.
Zurück zum Zitat Wild D et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30(10):1338-47 Wild D et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30(10):1338-47
3.
Zurück zum Zitat Hicks RJ, Hofman MS. Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat Rev Clin Oncol. 2012;9(12):712-20 Hicks RJ, Hofman MS. Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat Rev Clin Oncol. 2012;9(12):712-20
4.
Zurück zum Zitat Barrio M et al. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. J Nucl Med. 2017;58(5):756-61 Barrio M et al. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. J Nucl Med. 2017;58(5):756-61
5.
Zurück zum Zitat Hou J et al. Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021;8:771912 Hou J et al. Prognostic Value of Volume-Based Parameters Measured by SSTR PET/CT in Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2021;8:771912
6.
Zurück zum Zitat Werner RA et al. SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. J Nucl Med. 2018;59(7):1085-91 Werner RA et al. SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. J Nucl Med. 2018;59(7):1085-91
7.
Zurück zum Zitat Hope TA et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med. 2018;59(1):66-74 Hope TA et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med. 2018;59(1):66-74
8.
Zurück zum Zitat Kratochwil C et al. SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors. Mol Imaging Biol. 2015;17(3):313-8 Kratochwil C et al. SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors. Mol Imaging Biol. 2015;17(3):313-8
9.
Zurück zum Zitat Oksuz MO et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging. 2014;95(3):289-300 Oksuz MO et al. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging. 2014;95(3):289-300
10.
Zurück zum Zitat Qian ZR et al. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas. 2016;45(10):1386-93 Qian ZR et al. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas. 2016;45(10):1386-93
11.
Zurück zum Zitat Krenning EP et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496-506 Krenning EP et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history. Ann N Y Acad Sci. 1994;733:496-506
12.
Zurück zum Zitat Valkema R et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36(2):147-56 Valkema R et al. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med. 2006;36(2):147-56
13.
Zurück zum Zitat Kwekkeboom DJ et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124-30 Kwekkeboom DJ et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124-30
14.
Zurück zum Zitat Strosberg J et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125-35 Strosberg J et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125-35
15.
Zurück zum Zitat Brabander T et al. Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017;23(16):4617-24 Brabander T et al. Long-Term Efficacy, Survival, and Safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017;23(16):4617-24
16.
Zurück zum Zitat Parghane RV et al. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant (177)Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med. 2021;62(11):1558-63 Parghane RV et al. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant (177)Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med. 2021;62(11):1558-63
17.
Zurück zum Zitat Satapathy S et al. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'. Clin Endocrinol (Oxf). 2019;91(6):718-27 Satapathy S et al. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'. Clin Endocrinol (Oxf). 2019;91(6):718-27
18.
Zurück zum Zitat Righi L et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol. 2010;21(3):548-55 Righi L et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol. 2010;21(3):548-55
19.
Zurück zum Zitat Claringbold PG et al. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm. 2012;27(9):561-9 Claringbold PG et al. Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors. Cancer Biother Radiopharm. 2012;27(9):561-9
20.
Zurück zum Zitat Braat A et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 2020;21(4):561-70 Braat A et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol. 2020;21(4):561-70
21.
Zurück zum Zitat Kim C et al. Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020;8(2): e000980 Kim C et al. Phase I study of the (177)Lu-DOTA(0)-Tyr(3)-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020;8(2): e000980
22.
Zurück zum Zitat Ferdinandus J et al. Response to combined peptide receptor radionuclide therapy and checkpoint immunotherapy with ipilimumab plus nivolumab in metastatic Merkel cell carcinoma. J Nucl Med. 2022;63(3):396-8 Ferdinandus J et al. Response to combined peptide receptor radionuclide therapy and checkpoint immunotherapy with ipilimumab plus nivolumab in metastatic Merkel cell carcinoma. J Nucl Med. 2022;63(3):396-8
23.
Zurück zum Zitat Buder K et al. Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging. BMC Cancer. 2014;14:268 Buder K et al. Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging. BMC Cancer. 2014;14:268
24.
Zurück zum Zitat Vonken EPA et al. Intra-arterial administration boosts (177)Lu-HA-DOTATATE accumulation in salvage meningioma patients. J Nucl Med. 2022;63(3):406-9 Vonken EPA et al. Intra-arterial administration boosts (177)Lu-HA-DOTATATE accumulation in salvage meningioma patients. J Nucl Med. 2022;63(3):406-9
25.
Zurück zum Zitat Navalkissoor S, Grossman A. Targeted Alpha Particle Therapy for Neuroendocrine Tumours: The Next Generation of Peptide Receptor Radionuclide Therapy. Neuroendocrinology. 2019;108(3):256-64 Navalkissoor S, Grossman A. Targeted Alpha Particle Therapy for Neuroendocrine Tumours: The Next Generation of Peptide Receptor Radionuclide Therapy. Neuroendocrinology. 2019;108(3):256-64
Metadaten
Titel
Schwerpunkt "Theranostik"
Nicht nur bei NET: Somatostatinrezeptor-gerichtete Theranostik
verfasst von
PD. Dr. med. Manuel Weber
Publikationsdatum
12.04.2022
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 4/2022
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-022-9013-7

Weitere Artikel der Ausgabe 4/2022

InFo Hämatologie + Onkologie 4/2022 Zur Ausgabe

Onkologie aktuell

AML-Therapie bei Älteren

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.